Biotechnology company
Appears in 1 story
Co-developer of epcoritamab
AbbVie and Genmab said Monday that adding their bispecific antibody epcoritamab to the R-CHOP chemoimmunotherapy backbone cut the risk of disease progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma (DLBCL). It is the first phase 3 trial of a bispecific antibody to beat R-CHOP in the frontline setting — a regimen that has anchored treatment for over 20 years.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
